Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cervical Cancer
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04697628
- Collaborators
- Genmab
- Investigators
- Study Director: Shweta Jain, MD Seagen Inc. Study Director: Leo Nicacio Seagen Inc.